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Context: Medullary thyroid carcinoma (MTC) is a rare tumor originating from thyroid
parafollicular C cells. It has been previously demonstrated that insulin-like growth factor
I (IGF-I) protects MTC from the effects of antiproliferative drugs. Everolimus, an mTOR
inhibitor, has shown potent antiproliferative effects in a human MTC cell line, TT, and in
two human MTC primary cultures.
Objective: To verify whether IGF-I may influence the effects of everolimus in a group of
human MTC primary cultures.
Design: We collected 18 MTCs that were dispersed in primary cultures, treated without
or with 10 nM–1µM everolimus and/or 50 nM IGF-I. Cell viability was evaluated after
48 h, and calcitonin (CT) secretion was assessed after a 6 h incubation. IGF-I receptor
downstream signaling protein expression profile was also investigated.
Results: Everolimus significantly reduced cell viability in eight MTC [by ~20%; P<0.01
vs. control; everolimus-responders (E-R) MTCs], while cell viability did not change in
10 MTCs [everolimus-non-responders (E-NR) MTCs]. In E-R MTCs, IGF-I blocked the
antiproliferative effects of everolimus that did not affect CT secretion, but blocked the
stimulatory effects of IGF-I on this parameter. IGF-I receptor downstream signaling
proteins were expressed at higher levels in E-NR MTC as compared to E-R MTCs.
Conclusion: IGF-I protects a subset of MTC primary cultures from the antiproliferative
effects of everolimus and stimulates CT secretion by an mTOR mediated pathway that,
in turn, may represent a therapeutic target in the treatment of aggressive MTCs.
Keywords: IGF-I, medullary thyroid carcinoma, everolimus, mTOR, calcitonin
Introduction
Insulin-like growth factor I (IGF-I) system has been described in both rat (1) and humanmedullary
thyroid carcinoma (MTC) (2), where it stimulates DNA synthesis (3). In a humanMTC cell line, the
TT cells, IGF-I increases cell proliferation, DNA synthesis, and the percentage of cells in S phase,
all effects counteracted by co-incubation with either an IGF-I antibody or an IGF-I receptor (IGF-I
R) antibody (4). In addition, it has been previously demonstrated that IGF-I protects TT cells from
drug-induced cytotoxicity (5). Therefore, IGF-I may hamper the effects of antiproliferative drugs
in MTC.
Frontiers in Endocrinology | www.frontiersin.org May 2015 | Volume 6 | Article 631
Gentilin et al. IGF-I protects MTC from mTOR inhibition
New medical approaches became lately available for MTC,
thanks to the development of several agents that target tyrosine
kinases. Clinical trials have reported variable results, since patients
may develop drug resistance with consequent tumor progres-
sion (6). An alternative medical approach for neuroendocrine
tumors, including MTC, is represented by mTOR inhibitors,
such as everolimus. The latter displays antiproliferative effects on
a wide spectrum of tumors including neuroendocrine tumors,
both in vitro and in vivo (7–11). Moreover, it has been recently
demonstrated that everolimus inhibits cell viability in a dose-
and time-dependent fashion and reduces mTOR phosphorylation
in a human MTC cell line and in two human MTC primary
cultures (12). In addition, everolimus treatment of two patients
with progressive metastatic MTC was associated with disease sta-
bilization in one and disease progression in the other patient (13),
indicating that mTOR pathway may effectively control MTC cell
proliferation in a subset of patients. The variable effects of mTOR
inhibitors may be ascribed to independent signaling mechanisms,
activated by several growth factors, including IGF-I.
The aim of our study is therefore to verify whether IGF-I may
influence the effects of everolimus in a group of human MTC
primary cultures.
Materials and Methods
Materials
All reagents, if not otherwise specified, were purchased from
Sigma-Aldrich (Milano, Italy). Everolimus was provided by
Novartis Pharma (Basel, Switzerland).
Human MTCs
The samples derived from 18 patients diagnosed and operated on
for MTC at the Section of Endocrinology and Internal Medicine
of the University of Ferrara, and at the Department of Surgi-
cal, Oncological and Gastroenterological Sciences of the Uni-
versity of Padova. Table 1 shows patients’ characteristics and
pre-operative hormonal values. All patients (six males and 12
females; age= 52.1 3.9 years) underwent total thyroidectomy
with central neck lymph node dissection and had histological and
immunohistochemical diagnosis of MTC.
Tissue Collection and Primary Culture
Tissues were collected following the guidelines of the local com-
mittee on human research, and immediately minced in RPMI
1640 medium under sterile conditions. Primary cultures were
then prepared are described previously (14, 15). Cells were then
treated with test substances, with further evaluation of hormone
secretion and cell viability. Informed consent of the patients was
obtained for disclosing clinical investigation and performing the
in vitro study.
Cell Viability
The effects of everolimus and IGF-I on MTC cell viability in vitro
were assessed by ATPlite assay (Perkin-Elmer, Monza, Italy) on
the Wallac Victor™ 1420 Multilabel Counter (Perkin-Elmer) as
previously described (16). Cells were treated after 24 h with or
without 10 nM–1 µMeverolimus and/or 50 nM IGF-I. Treatments
TABLE 1 |MTC patients clinical characteristics.
No. Sex Age Plasma CT (pg/ml) Stage Inheritance
1 M 46 157 II SP
2 M 40 1500 II FMTC
3 M 47 940 II MEN2A
4 M 39 1500 II SP
5 F 35 700 II SP
6 F 32 28 II MEN2A
7 F 35 74 I SP
8 F 33 19 I FMTC
9 F 42 153 II SP
10 M 52 207 II SP
11 F 44 2350 II SP
12 M 56 1258 II SP
13 F 79 1500 III SP
14 F 71 2578 III SP
15 F 73 3848 IVc SP
16 F 75 1500 III SP
17 F 69 3405 III SP
18 F 70 9227 IVb SP
FMTC, familial medullary thyroid carcinoma; MEN2A, MEN2A RET mutation; SP, sporadic
disease.
were renewed after the first 24 h of incubation. Cell viability was
assessed after 48 h. Results were obtained by determining the
mean value of six replicates.
Protein Expression Panel
Tissues were dissolved in cell lysis buffer (Bio-Rad, Milano, Italy)
supplemented with cell lysis factor QG (Bio-Rad, Milano, Italy)
and 2mM phenylmethanesulfonylfluoride. Protein concentration
was measured by BCA Protein Assay Reagent Kit (Pierce, Rock-
ford, IL, USA), as previously described (17). Bio-plex®/Luminex®
Technology (Bioclarma Research and Molecular Diagnostics,
Torino, Italy) was employed to assess total protein levels of IGF-
I receptor (IGF-I R), AKT, p70S6K, p38MAPK, ERK1/2, and
CREB in MTC tissue samples. The following phosphorylated
forms were also investigated: p(Tyr1131) IGF-I R, p(Ser473)
AKT, p(Thr421/Ser424) p70S6K, p(Thr180/Tyr182) p38MAPK,
p(Thr202/Thr204,Thr185/Thr187) ERK1/2, and p(Ser133) CREB
levels.
Calcitonin Assay
Calcitonin (CT) was measured in conditioned medium from pri-
mary cultured cells by an ELISA kit (DRG, Springfield, NJ, USA),
after a 6 h treatment without or with the test substances. The
intra- and inter-assay variation coefficients were 2.8–5.7% and
6.1–7.4%, respectively. The detection limit was 1.0 pg/ml. Assays
were performed in duplicate.
Statistical Analysis
Fisher exact test was used to evaluate the association between
clinical characteristics of the patients and MTC primary culture
responsivity to everolimus in terms of cell viability reduction.
Results are expressed as the mean standard error of the mean
(SEM). A Student’s paired or unpaired t test was used to evaluate
the individual differences between means.
P-values< 0.05 were considered significant.
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Results
Effects of Everolimus on Cell Viability
Todetermine the effects of everolimus on cell viability of dispersed
MTC cells, we assessed cell viability in MTC primary cultures
after a 48 h treatment with 10 nM–1 µM everolimus. According
to the extent of cell viability reduction recorded after treatment
with everolimus, the primary cultures were divided in two groups:
the cultures responding to any everolimus concentration with
a significant (P< 0.05) cell viability reduction were considered
as “everolimus-responders” (E-R), while those displaying a non-
significant cell viability variation were considered as “everolimus-
non-responders” (E-NR). According to this criterion, cultures
from eight MTC were considered as E-R and 10 as E-NR.
Evaluating the patients clinical charts, we found that mean CT
plasma levels of patients which primary cultures belonged to the
E-NR group were ~fourfold higher than the mean CT plasma
levels of patients which primary cultures belonged to the E-R
group (P= 0.054). In addition, disease stage and inheritance were
differently distributed among patients which primary cultures
belonged to the E-R and those which primary cultures belonged
to the E-NR group. In particular, E-NR MTCs were significantly
associated with a disease stage III (P< 0.02) and with sporadic
disease (P< 0.03).
In the E-R group (black bars), everolimus dose-dependently
reduced cell viability, from –19% at 10 nM to –31% vs. control
at 1 µM (P< 0.01). In the E-NR MTCs (white bars), everolimus
did not significantly modify cell viability (Figure 1). Further
experiments were carried out only in the E-R group.
Protein Profiling
In a subset of MTC samples (including two E-R and four E-NR
MTCs), we had a sufficient tissue amount that allowed us to inves-
tigate protein expression profile. We then assessed total and phos-
phorylated protein levels of IGF-I R, AKT, p70S6K, p38MAPK,
ERK1/2, and CREB. We found that total IGF-I R, p70S6K,
FIGURE 1 | Effects of everolimus on MTC primary culture cell viability.
MTC primary cultures were incubated in 96-well plates for 48 h in culture
medium supplemented with everolimus at increasing concentrations from
10nM to 1 µM, and control cells were treated with vehicle solution. Data from
18 MTC primary cultures were evaluated independently with six replicates
each, and were expressed as the meanSEM percent cell viability vs.
control cells. **P<0.01 vs. control cells. As described in the Section
“Results,” MTCs were divided according to cell viability inhibition after
treatment with everolimus in E-R (eight samples, black bars) and E-NR (10
samples, white bars).
p38MAPK, ERK1/2, and CREB protein levels were higher in E-
NR MTCs as compared to E-R MTCs (+153%, +259%, +68%,
+53%, and +1735%, respectively). Statistical significance was
observed for total CREB protein levels in E-NR MTCs vs. E-R
MTCs (P< 0.02). On the contrary, total AKT protein levels were
similar in the two groups (Figure 2A). In addition, phospho-
rylated IGF-I R, AKT, p70S6K, p38MAPK, and CREB protein
levels were higher in E-NR MTCs as compared to E-R MTCs
(+10%,+32%,+200%,+165%, and+426%, respectively). On the
contrary, phosphorylated ERK1/2 protein levels were similar in
the two groups (Figure 2B).
Effects of IGF-I on Cell Viability in
Everolimus-Responder MTCs
To investigate whether everolimus inhibitory effectsmight involve
growth factor activated pathways, cell viability was assessed in E-R
MTC cultures treated with or without 50 nM IGF-I, in the pres-
ence or in the absence of 10 nM–1 µM everolimus. IGF-I did not
significantly affect cell viability, but counteracted the inhibitory
effects of everolimus at all concentrations tested (Figure 3).
Effects of IGF-I on CT Secretion in
Everolimus-Responder MTCs
To determine the effects of everolimus on CT secretion by dis-
persed MTC cells, we assessed CT concentrations in conditioned
medium from the eight E-R MTC cultures. CT levels were not
significantly influenced by treatment with everolimus at any con-
centration tested. On the other hand, IGF-I significantly induced
CT secretion (+19%; P< 0.01 vs. control), an effect that was
reduced by co-incubation with everolimus at all concentrations
tested (Figure 4).
FIGURE 2 |MTC protein profiling. MTC tissues were dissolved as
described in the Section “Material and Methods” and assessed by
Bio-plex®/Luminex® Technology. Total (A) and phosphorylated (B) protein
levels of IGF-I R, AKT, p70S6K, p38MAPK, ERK1/2, and CREB were assayed
in E-R (black bars) and E-NR (white bars) samples. *P<0.05 vs. E-R MTCs.
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FIGURE 3 | Effects of IGF-I on MTC primary culture cell viability. MTC
primary cultures were incubated in 96-well plates for 48 h in culture medium
supplemented with everolimus at increasing concentrations from 10nM to
1 µM, and control cells were treated with vehicle solution. Data from 18 MTC
primary cultures were evaluated independently with six replicates each, and
were expressed as the meanSEM percent cell viability vs. control cells.
**P<0.01 vs. control cells. E-R MTC were incubated with (dashed bars) or
without 50 nM IGF-I (black bars).
FIGURE 4 | Effects of everolimus and IGF-I on CT secretion by E-R
MTCs. E-R MTC primary cultures were incubated in 96-well plates for 6 h in
culture medium supplemented with indicated substances. Control cells were
treated with vehicle solution. CT secretion by each primary culture was then
measured by ELISA. Data from eight E-R MTC primary cultures were
evaluated independently with two replicates each and were expressed as the
meanSEM percent CT secretion vs. control cells. *P<0.05 and **P<0.01
vs. control cells. #P<0.05 vs. IGF-I treated cells.
Discussion
This study demonstrates that IGF-I influences the effects of
everolimus in a sub-group of human MTC primary cultures,
supporting the hypothesis that IGF-I may hamper the effects of
antiproliferative drugs in MTC. In addition, our results indicate
that mTOR inhibitors may be effective in restraining cell pro-
liferation only in a subset of MTCs, in keeping with previously
reported in vivo data (13, 18). Indeed, Lim et al. show that only
one out of the nineMTC patients treated with everolimus displays
a ~20% reduction in tumor bulk, while the other patients show
either stable or progressive disease (18). These data support the
hypothesis that other survival pathways, including those activated
by RET mutations, are active in MTC and may hamper the effects
of mTOR inhibitors. The latter may be cytostatic, since it has been
demonstrated that everolimus treatment of pancreatic neuroen-
docrine tumor (pNET) and MTC cell lines inhibits cell growth by
increasing the G0/G1 phase of the cell cycle (12, 19). Moreover,
it is widely demonstrated that mTOR inhibition has a significant
antiproliferative effect on pNET cell lines (20) as well as on other
tumor cells (8, 9).
Insulin-like growth factor I is confirmed as a protective growth
factor toward C-cell survival, in keeping with previous evidence
(21). Our data confirm that IGF-I does not stimulate cell pro-
liferation of MTC primary cultures, but protects them from the
effects of everolimus, suggesting that escape from therapy may
occur in the presence of IGF-I or similar growth factors. This
hypothesis is further strengthened by the finding that E-NRMTC
display higher levels of IGF-I R and therefore may possibly be
more sensitive to the protective effects of IGF-I. Indeed, we
observed that IGF-I R displays higher phosphorylation levels
in E-NR MTC as compared to E-R MTCs. This finding is in
keeping with a greater activation of the IGF-I pathway, as also
supported by higher phosphorylation levels (i.e., activation) of
IGF-I downstream signaling proteins.Moreover,MTCs belonging
to the E-NR group are significantly associated with sporadic and
higher disease stage, indicating that this group represents a more
aggressive disease.
In addition, we found that mTOR pathway is activated inMTC,
as previously reported (22), especially in E-NR as compared to
E-R MTCs. This finding indicates that mTOR signaling pathway
over-activation is not invariably a marker of sensitivity to mTOR
inhibitors in all endocrine and endocrine-related tumors (7, 9,
23). However, further studies are needed to identify a prognostic
protein panel that may accurately predict responsivity of MTCs to
mTOR inhibitors on clinical grounds.
Our results confirm that IGF-I promotes CT secretion in a
subset ofMTC primary cultures, as previously demonstrated (21).
In addition, we found that this effect is hampered by everolimus,
indicating that IGF-Imodulates CT secretion involving themTOR
pathway, which, in turn, may regulate CT secretion only in
response to secretory stimuli, such as IGF-I. It has been previously
shown that IGF-I stimulates hormone secretion in parathyroid
cells bymodulating calcium channels (24) that are present inMTC
cells (25). Calcium-dependent signaling pathways are induced by
IGF-I through CREB phosphorylation (26) that, in turn, regulates
CT secretion (27). Higher levels of both total and phosphory-
lated CREB protein were found in E-NR MTCs, that also display
higher IGF-I R levels and higher CT plasma levels, supporting the
hypothesis that IGF-I systemmay be over-activated and may pro-
mote CT secretion in E-NRMTCs. These tumors, despite display-
ing aggressive characteristics, may anyway benefit from treatment
with everolimus, since this drugmay control CT secretion. Indeed,
as shown in the available clinical studies, everolimus treatment is
effective in significantly reducing circulatingCTplasma levels also
when no effect on tumor bulk was apparent (13, 18, 28).
Our results also indicate that everolimus treatment may not
result in both tumor growth control andhormone secretion reduc-
tion in all MTCs, as also previously found for treatment with
somatostatin analogs, that could exert antiproliferative effects
despite the lack of antisecretory activity and vice versa (14). These
finding suggest that proliferation and secretion are controlled by
two different mechanisms in human MTC.
In conclusion, our data show that IGF-I protects MTC pri-
mary cultures from the effects of everolimus and stimulates CT
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secretion by an mTOR mediated pathway that, in turn, may rep-
resent a therapeutic target in the treatment of aggressive MTCs. A
synergistic effect of IGF-IR inhibitors and everolimus has already
been hypothesized (29, 30). Indeed, mTOR inhibition increases
Akt activity via the IGF-IR pathway, leading to the reduction of
mTOR inhibitor effects (30). Therefore, IGF-IR signaling inhibi-
tion may prevent this positive feedback mechanism. The results
of ongoing clinical trial employing both everolimus and the
somatostatin receptor pan-agonist Pasireotide (SOM230 alone or
in combination with RAD001 in patients with medullary thyroid
cancer; NCT01625520) may help in clarifying this issue, also on
the basis of the potent inhibitory effects of Pasireotide on IGF-I
secretion.
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